MGC Pharmaceuticals Ltd.

Audited Annual Financial Report for the year ended 30 June 2021

 and Corporate Governance Statement

30 September 2021

ASX, LSE: MXC

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') is pleased to provide the following documents with respect to the financial year ended 30 June 2021:

·    Audited Annual Financial Report for the year ended 30 June 2021

A copy of the Audited Annual Financial Report can be found at the following URL:

https://www.asx.com.au/asxpdf/20210930/pdf/4513g2gq6tnlq2.pdf 

·    ASX Appendix 4G "Key disclosures - Corporate Governance Council Principles and Recommendations" and MGC Pharma's Corporate Governance Statement for the year ended 30 June 2021.

A copy of the Appendix 4G and Corporate Governance Statement can be found at the following URL:

https://www.asx.com.au/asxpdf/20210930/pdf/4513h35gmdkclw.pdf  

--Ends--

Authorised for release by the Board, for further information please contact:

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally.  The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline. 

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.  

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. 

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma